Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by RMR Wealth Builders

RMR Wealth Builders boosted its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 15.3% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 2,965 shares of the pharmaceutical company’s stock after acquiring an additional 393 shares during the period. RMR Wealth Builders’ holdings in Vertex Pharmaceuticals were worth $1,206,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Arlington Trust Co LLC lifted its stake in Vertex Pharmaceuticals by 97.1% in the 4th quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 33 shares in the last quarter. Fortitude Family Office LLC acquired a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at approximately $30,000. Baystate Wealth Management LLC lifted its position in Vertex Pharmaceuticals by 49.0% during the fourth quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock worth $31,000 after buying an additional 25 shares in the last quarter. OFI Invest Asset Management purchased a new stake in Vertex Pharmaceuticals in the 3rd quarter valued at $25,000. Finally, NBC Securities Inc. acquired a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter worth $34,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Up 2.1 %

Shares of NASDAQ:VRTX opened at $418.82 on Thursday. Vertex Pharmaceuticals Incorporated has a 52 week low of $320.01 and a 52 week high of $448.40. The company’s 50 day moving average is $408.02 and its two-hundred day moving average is $400.75. The company has a market cap of $108.25 billion, a PE ratio of 30.15, a P/E/G ratio of 1.89 and a beta of 0.39. The company has a current ratio of 3.99, a quick ratio of 3.78 and a debt-to-equity ratio of 0.02.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 EPS for the quarter, beating the consensus estimate of $3.66 by $1.10. The firm had revenue of $2.69 billion for the quarter, compared to analyst estimates of $2.58 billion. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. Vertex Pharmaceuticals’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.67 earnings per share. Equities analysts predict that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Amit Sachdev sold 3,222 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $1,354,013.28. Following the completion of the transaction, the executive vice president now directly owns 74,364 shares of the company’s stock, valued at $31,250,727.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP Amit Sachdev sold 3,222 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,354,013.28. Following the completion of the sale, the executive vice president now directly owns 74,364 shares of the company’s stock, valued at $31,250,727.36. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Ourania Tatsis sold 354 shares of the firm’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $425.70, for a total value of $150,697.80. Following the transaction, the executive vice president now directly owns 55,804 shares in the company, valued at approximately $23,755,762.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,381 shares of company stock worth $5,203,249. 0.20% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

VRTX has been the topic of several recent research reports. Truist Financial boosted their price target on shares of Vertex Pharmaceuticals from $456.00 to $508.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. JPMorgan Chase & Co. increased their price objective on Vertex Pharmaceuticals from $390.00 to $438.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Guggenheim lifted their target price on Vertex Pharmaceuticals from $445.00 to $450.00 and gave the company a “buy” rating in a research report on Thursday, April 18th. Canaccord Genuity Group reiterated a “sell” rating and set a $371.00 price target on shares of Vertex Pharmaceuticals in a report on Friday, April 12th. Finally, Canaccord Genuity Group lowered shares of Vertex Pharmaceuticals from a “hold” rating to a “sell” rating and increased their target price for the stock from $332.00 to $379.00 in a research note on Wednesday, January 24th. Three analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $432.18.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.